SAB Biotherapeutics, Inc.SABSEarnings & Financial Report
Nasdaq · Health Care · Biological Products, (No Diagnostic Substances)
SAB Biotherapeutics is a clinical-stage biopharmaceutical company that develops novel fully human polyclonal antibody therapies leveraging its proprietary transchromosomic cattle platform. Its product pipeline targets unmet medical needs across infectious diseases, autoimmune conditions, and oncology, serving global patient populations.
Top Holders
| Holder | % Owned | Shares | Change | As of |
|---|---|---|---|---|
| RTW Investments, LP | 9.99% | 9.2M | — | 2024-02-14 |
| Biotechnology Value Fund, L.P. | 5.30% | 4.9M | — | 2023-12-04 |
| Commodore | 3.50% | 1.8M | ▼ -6.40pp | 2024-02-14 |
| Radcliffe Capital Management, L.P. | 0.00% | 2.1K | — | 2024-02-14 |
Insider Transactions
Net 90d: +$0 · buys $0 / sells $0Range:
Action:
Role:
No transactions match these filters.